Rabbani Faezeh, Raeisi Mohsen, Keivanfar Majid, Saffaei Ali, Sabzghabaee Ali Mohammad
Pharmacy Students' Research Committee, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Pediatric Pulmonology, Imam Hossein Children's Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
J Res Pharm Pract. 2023 Mar 24;11(3):116-123. doi: 10.4103/jrpp.jrpp_77_22. eCollection 2022 Jul-Sep.
We aimed to evaluate the efficacy of an oral combined tablet of (Anti-Asthma) as an add-on therapy for the relief of the severity of symptoms in mild-to-moderate childhood asthma.
This randomized placebo-controlled clinical trial was performed on 60 children and adolescents with chronic mild-to-moderate childhood asthma. Patients were randomly divided into cases who received Anti-Asthma oral combined tablets 2 tablets twice dailt for 1 month and controls, received placebo tablets identically the same to Anti-Asthma (2 tablets, twice daily, for 1 month) as add-ons to their standard therapy according to the guideline. The severity and frequency of cough attacks and shortness of breath, respiratory test indices (based on spirometry), and the extent of disease control and treatment adherence were measured clinically by validated questionnaires at the beginning and after the study.
Respiratory test indices improved and the severity of activity restriction decreased significantly in the cases compared to the controls However, the mean difference before and after the study was significantly different between the cases and controls only for the number and severity of coughs and the severity of activity restriction. In the scores of the Asthma Control Questionnaire, the cases group had a significant improvement compared to the controls.
Anti-Asthma oral formulation may be effective as an adjunct add-on treatment in the maintenance therapy of mild-to-moderate childhood asthma.
我们旨在评估一种口服复方片剂(抗哮喘)作为附加疗法缓解轻度至中度儿童哮喘症状严重程度的疗效。
这项随机安慰剂对照临床试验对60名患有慢性轻度至中度儿童哮喘的儿童和青少年进行。患者被随机分为两组,一组接受抗哮喘口服复方片剂,每日两次,每次2片,共1个月;另一组为对照组,接受与抗哮喘片剂外观相同的安慰剂片剂(每日两次,每次2片,共1个月),作为其标准治疗的附加治疗。根据指南,在研究开始时和结束后,通过经过验证的问卷临床测量咳嗽发作和呼吸急促的严重程度和频率、呼吸测试指标(基于肺功能测定)以及疾病控制程度和治疗依从性。
与对照组相比,病例组的呼吸测试指标有所改善,活动受限的严重程度显著降低。然而,病例组和对照组在研究前后的平均差异仅在咳嗽的次数和严重程度以及活动受限的严重程度方面有显著差异。在哮喘控制问卷的评分中,病例组与对照组相比有显著改善。
抗哮喘口服制剂作为轻度至中度儿童哮喘维持治疗的辅助附加治疗可能有效。